Bristol Myers Squibb stock: Goldman Sachs upgrades Bristol Myers Squibb stock to strong buy

Published on 10/23/2026 at 16:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 29, 2026, and quarterly revenue was USD 12.97 billion. Bristol Myers Squibb stock costs EUR 55.59 on October 23, 2026.

Rating and reporting date

Goldman Sachs upgraded Bristol Myers Squibb from hold to strong buy on October 17, 2026.
Bristol Myers Squibb will report third-quarter 2026 results on October 29, 2026.
Bristol Myers Squibb stock costs EUR 55.59 at Lang & Schwarz on October 23, 2026 at 4:07 p.m. CEST.
The market capitalization stood at USD 125.9 billion on October 23, 2026.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb stock (ISIN US1101221083) has a fresh rating signal: Goldman Sachs upgraded the company from hold to strong buy in a report dated October 17, 2026, as MarketBeat reported. At Lang & Schwarz, the stock was trading at EUR 55.59 on October 23, 2026 at 4:07 p.m. CEST.

Goldman Sachs changes the rating

The upgrade moves Goldman Sachs from a neutral stance to a distinctly positive one, but the report did not provide a new price target. The same MarketBeat report said the average analyst target was USD 64.88 and that 30 analysts covered the company on October 17, 2026.

The rating change comes while Bristol Myers Squibb is preparing to show more pipeline data at the European Society for Medical Oncology congress. The company had announced 12 oral presentations and nearly 60 disclosures for the October 23 to October 27, 2026 event in Madrid in a release dated October 19, 2026, according to Business Wire.

What comes next for the stock?

Bristol Myers Squibb has scheduled its third-quarter 2026 results conference call for October 29, 2026, according to its investor calendar. In the second quarter of 2026, revenue reached USD 12.97 billion, up 5.70 percent from the prior year, while adjusted earnings per share came to USD 2.04, beating the USD 1.60 consensus estimate, MarketBeat reported on October 17, 2026.

Price and valuation frame

The primary-market quote was USD 61.65 on the NYSE at 10:19 a.m. ET on October 23, 2026. The same session showed 1,087,161 shares traded, while Bristol Myers Squibb's 52-week range was USD 42.52 to USD 68.64. Its price-to-earnings ratio was 13.60 and its market capitalization was USD 125.9 billion on October 23, 2026.

For comparison, AbbVie traded at USD 283.52 on October 23, 2026, with a price-to-earnings ratio of 79.81 and a market capitalization of USD 501.0 billion. Eli Lilly traded at USD 1,277.76, with a price-to-earnings ratio of 42.98 and a market capitalization of USD 1.2 trillion on the same date. These figures place Bristol Myers Squibb at a lower earnings multiple than both peers, although the companies have different product portfolios and growth profiles.

Investor calendar sets the next date

The October 29 reporting date is the next scheduled company event. The latest reported quarter combined USD 12.97 billion in revenue with adjusted earnings per share of USD 2.04, giving investors a clear comparison point for the third-quarter update.

Stock price in Germany

The euro quote stood at EUR 55.59 at Lang & Schwarz on October 23, 2026 at 4:07 p.m. CEST. The primary-market price was USD 61.65 on the NYSE at 10:19 a.m. ET on October 23, 2026. The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.